Brother of regulator of imprinted sites inhibits cisplatin-induced DNA damage in non-small cell lung cancer

Cisplatin (DDP) chemotherapy is the primary modality of treatment for non-small cell lung cancer (NSCLC). However, due to the occurrence of DDP resistance, only a limited number of patients benefit from this treatment regimen. Brother of Regulator of Imprinted Sites (BORIS) is expressed elevated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yanmei, Song, Yongfei, Li, Chao, Ren, Juan, Fang, Mengdie, Fang, Jianfei, Wang, Xiaoju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509674/
https://www.ncbi.nlm.nih.gov/pubmed/32994814
http://dx.doi.org/10.3892/ol.2020.12114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509674/
https://www.ncbi.nlm.nih.gov/pubmed/32994814
http://dx.doi.org/10.3892/ol.2020.12114

Ejemplares similares